We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simple Blood Test Diagnoses Bipolar Disorder More Accurately

By LabMedica International staff writers
Posted on 26 Oct 2023
Print article
Image: The blood test offers a new way of improving diagnosis of bipolar disorder (Photo courtesy of 123RF)
Image: The blood test offers a new way of improving diagnosis of bipolar disorder (Photo courtesy of 123RF)

Bipolar disorder is a condition that affects about 1% of the global population, which translates to roughly 80 million people. However, nearly 40% of those affected are incorrectly diagnosed with major depressive disorder, a condition that requires a different treatment approach. Incorrectly treating bipolar disorder with antidepressants without the use of mood stabilizers can induce a manic episode. Currently, a comprehensive psychiatric evaluation is the most reliable method for diagnosing bipolar disorder, but these assessments often have long waiting times and are time-consuming. Now, a simple blood test with the ability to diagnose bipolar disorder could ensure that patients receive the right treatment the first time and also reduce the strain on healthcare providers.

Researchers at the University of Cambridge (Cambridge, UK) have created a novel diagnostic approach that employs a simple blood test to identify biomarkers linked to bipolar disorder. By combining an online psychiatric evaluation with the blood test, the team managed to correctly diagnose several patients who were previously misdiagnosed with major depressive disorder. On its own, the blood test could accurately diagnose bipolar disorder in up to 30% of patients. However, its efficacy improved notably when used alongside a digital mental health assessment. The inclusion of biomarker tests could assist doctors in distinguishing between major depressive disorder and bipolar disorder, conditions that exhibit similar symptoms but necessitate different drug treatments.

For their research, the team relied on samples and information gathered from the Delta study, which took place in the UK from 2018 to 2020. The study aimed to identify bipolar disorder among patients who had been diagnosed with major depressive disorder in the last five years and were currently experiencing depressive symptoms. The participants, who numbered over 3000, were enlisted online and completed an extensive online mental health questionnaire containing over 600 questions. Topics covered by the questionnaire included past and present depressive episodes, generalized anxiety, symptoms of mania, family history, and substance abuse. Out of those, around 1000 participants were chosen to provide a dried blood sample through a finger prick. The samples were then analyzed for over 600 different metabolites using mass spectrometry. After completing a thorough and validated diagnostic tool, the Composite International Diagnostic Interview, 241 participants were finally selected for the study.

Upon analyzing the data, the researchers identified a significant biomarker signal for bipolar disorder that was evident even after adjusting for variables like medication. Validation was performed on a separate group of patients who were clinically diagnosed with either major depressive disorder or bipolar disorder during the study's one-year follow-up. The combination of self-reported data and the biomarker test showed a significant enhancement in diagnosing bipolar disorder, particularly in cases where the diagnosis was not immediately evident. While the blood test is still in the proof-of-concept stage, the researchers believe it could serve as a valuable adjunct to existing diagnostic methods and may shed light on the biological origins of mental health disorders.

“The online assessment was more effective overall, but the biomarker test performs well and is much faster,” said Professor Sabine Bahn, who led the research. “A combination of both approaches would be ideal, as they’re complementary. In addition to the diagnostic capabilities of biomarkers, they could also be used to identify potential drug targets for mood disorders, which could lead to better treatments.”

Related Links:
University of Cambridge 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
AST Cards
Antimicrobial Susceptibility Testing Cards
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.